Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: A Southwest Oncology Group study

Blood

Volumn 100, Issue 1, 2002, Pages 29-35

  Wolman, Sandra R ^a,b,c,d,e,f   Gundacker, Holly ^a,b,c,d,e   Appelbaum, Frederick R ^a,b,c,d,e   Slovak, Marilyn L ^a,b,c,d,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b Universities Associated for Research and Education in Pathology (UAREP)   (United States)

^c SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC DISORDER; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TRISOMY 8;

EID: 0036660162     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.29     Document Type: Article

References (20)

1. Huret JL. +8 or trisomy 8. Atlas Genet Cytogenet Oncol Haematol. Accessed November 1998. Available at: http://www.infobiogen.fr/services/chromcancer/Anomalies/tri8ID1017.html.
2. Byrd JC, Lawrence D, Arthur DC, et al. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from cancer and leukemia group B 8461. Clin Cancer Res. 1998;4:1235-1241.
3. Elliott MA, Letendre L, Tefferi A, Hanson CA, Dewald GW. Trisomy 8 in acute myeloid leukemia (AML) [abstract]. Blood. 2000;96;708.
4. Pedersen B. MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases. Am J Hematol. 1997;56:224-229.
5. Schoch C, Haase D, Fonatsch C, et al. The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol. 1997;99:605-611.
6. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111:801-806.
7. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (S9031). Blood. 1998;91:3607-3615.
8. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
9. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
10. Seghezzi L, Maserati E, Minelli A, et al. Constitutional trisomy 8 as first mutation in multistep carcinogenesis: clinical, cytogenetic, and molecular data on three cases. Genes Chromosomes Cancer. 1996;17:94-101.
11. Kapaun P, Kabisch H, Held KR, Walter TA, Hegewisch S, Zander AR. Atypical chronic myelogenous leukaemia in a patient with trisomy 8 mosaicism syndrome. Ann Hematol. 1993;66:57-58.
12. Hasle H, Clausen N, Pedersen B, Bendix-Hansen K. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet. 1995;79:79-81.
13. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323-3329.
14. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia (AML): a Southwest Oncology/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187.
17. Mayer RJ, Schiffer CA, Petterson BA, et al. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of Ara-C: a progress report from the CALGB. Semin Oncol. 1987;14(suppl 1):25-31.
18. Sole F, Espinet B, Sanz G, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108:346-356.
19. Virtaneva K, Wright FA, Tanner SM, et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A. 2001;98:1124-1129.
20. Jennings BA, Mills KI. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res. 1998;22:899-903.